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Background: The Y-75 (Ginsan) acidic polysaccharide from Korean Panax ginseng has been shown to function as
an immunomodulatory molecule. However, the efficacy of Y-75 has not been evaluated in clinical trial.
Methods: We verified Y-75 (6 g/day) for safety and immune efficacy in 72 healthy volunteers aged 50–75 years
using a randomized, placebo-controlled, parallel, double-blind study. The activities of natural killer (NK) cells and
peripheral blood phagocytes, as well as serum levels of monocyte-derived mediators, were assessed before and
after administration for 8 and 14 weeks. This trial is registered at ClinicalTrials.gov (NCT02161198).
Results: Y-75 significantly enhanced NK cell cytotoxic activity by 35.2% and 40.2% from baseline after administration for
8 and 14 weeks, respectively. The phagocytic activity of peripheral blood cells was also significantly increased by 25.2%
and 39.4% and serum level of TNF-α by 38.2% and 44.5% after treatment for 8 and 14 weeks, respectively. Differences in
the efficacy of variables compared to the placebo group were also significant. Administration of Y-75 was well tolerated
without treatment-related adverse events or alteration of complete blood cell count or blood chemistry over the entire
study period.
Conclusion: Y-75 was shown to be a safe and potentially effective natural alternative for enhancing immune function.
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The root of Panax ginseng CA Meyer is an established
traditional herbal medicine in Asia, having been used for
thousands of years, and is now used worldwide as a
nutraceutical source to improve physical performance,
boost resistance against infection, reduce risk of cancer,
and support current therapeutic modalities for some
chronic diseases [1,2]. The biological actions of ginseng
are unclear, but it appears that some of its effects are
related to immunomodulation [3].
More than 100 different chemical entities of biological
Interest, including ginsenosides, polysaccharides, polyacety-
lenes, and peptides, have been derived from ginseng species* Correspondence: kskim@catholic.ac.kr
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unless otherwise stated.and their metabolites [4]. Among them, the polysaccharides
have been shown to have effects on immunologic defense
functions [5,6]. The mechanisms of action have not been
fully elucidated at the molecular level, but these have been
shown to activate many of the diverse types of cells in the
immune system [7,8] and stimulate production of various
cytokines [9-12]. A number of pharmacologically active
polysaccharides with molecular weights ranging from
3500 to 160,000 Da have been identified. Importantly,
these polysaccharides consist primarily of neutral
sugars with various molar ratios depending on the specific
ginseng of origin [4].
Ginsan is an acidic polysaccharide with a molecular
weight of 150,000 Da, isolated from the aqueous
Korean Panax ginseng extract [13,14]. Previous studies
have shown that Ginsan induces the proliferation of
lymphocytes [15] and maturation of bone-marrow
derived dendritic cells [16,17] as well as stimulates
the phagocytic activity of macrophages [18,19]. These. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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kines, including interleukin-1β, interleukin-2, interleukin-6,
interleukin-12 (IL-12), interferon-γ, and tumor necro-
sis factor-α (TNF-α) [14,16,18-24]. In addition, Ginsan
enhances the antibody response to orally administered
Salmonella antigen in a mouse model [25]. Finally,
pretreatment of Ginsan protects mice from lethality
induced by Staphylococcus aureus infection [26,27]. This
survival benefit is associated with enhanced bacterial clear-
ance from circulation and attenuation of the acute elevation
of cytokines in the early septic phase, the uncontrolled
response of which may be harmful to the host. Taken
together, these observations strongly suggest that Ginsan
mediates a significant modulatory effect on the immune
system. However, the efficacy of Ginsan has not been
studied in clinical trials.
Ginsan is currently available as an over-the-counter prep-
aration and is used as a natural alternative to proactively
strengthen immunity. The present study performed a
randomized, placebo-controlled clinical trial to evaluate the
safety and beneficial effects of Ginsan, denoted as Y-75, on
immune function in a group of healthy adults aged between
50 and 75 years. The focus of this trial was modulation of
innate immunity, comprising cytotoxic activity of natural
killer (NK) cells, phagocytic activity of polymorphonuclear
(PMN) leukocytes and mononuclear phagocytes, and serum
levels of monocyte-derived mediators.
Subjects and methods
Participants
Volunteers were required to be in good general health and
from 50 to 75 years of age. Exclusion criteria were based
on patient history and included the following medical
conditions: human immunodeficiency virus-1 infection
and malignancy; active (currently requiring adjustment of
medications) cardiovascular, renal, pulmonary, hepatic,
endocrine, hematologic, neurological or psychiatric disease;
recent (within 4 weeks) acute respiratory tract symptoms.
Volunteers were also excluded if, at the time of enrollment,
they were prescribed concurrent immunosuppressive
therapy including cytotoxic agents and corticosteroids,
any medication (within 4 weeks) deemed likely to interfere
with the evaluation (e.g., other herbal products), or
had a history of allergic or other adverse reactions to
ginseng products.
Procedures and measures
This study was conducted as a single-center, randomized,
placebo-controlled, parallel, double-blind trial from
September 2012 to April 2013 at Seoul St. Mary’s
Hospital, The Catholic University of Korea. The study
protocol, approved by the institutional review board
of Seoul St. Mary’s Hospital, The Catholic University
of Korea (KC12HISI0270), was conducted in accordancewith the Declaration of Helsinki. Informed consent was
obtained from all volunteers before entering the trial.
Qualifying volunteers were randomly assigned in a 1:1 ratio
to receive Y-75 at a dose of 3 g twice a day or a matching
placebo. Laboratory data for safety assessment and baseline
(prior to the initial dose) data for efficacy variables were
obtained at screening and on the first day of investigational
product administration, respectively. During scheduled visits
at 8 and 14 weeks after the administration, participants were
assessed for safety, efficacy, and compliance.
The primary efficacy variable was the mean percentage
change in NK cell activity from a baseline level in
response to Y-75. NK cells were isolated from peripheral
blood of subjects at baseline, week 8 and 14 and their
cytotoxic activities were measured against the K-562
tumor cell targets using a standard 51Cr release assay.
Briefly, the target cells were labeled with 200 μCi of
Na51CrO4 (PerkinElmer Life Science, USA) for 1 h,
washed, and then incubated with the isolated NK cells at
different effector-to-target cell ratios for 4 h. After incuba-
tion, 100 μl of the supernatant of each well was collected
and measured using a Gamma counter (Cobra 2 auto
gamma, Packard, Downers Grove, IL). The percentage of
specific lysis was determined using the following formula:
[(experimental release – spontaneous release)/(maximum
release – spontaneous release)] × 100. The spontaneous
and maximum releases were determined by incubating the
target cells without the effectors in the medium alone or in
10% SDS, respectively. The spontaneous release was always
<10% of the maximum release. Secondary efficacy variables
included changes from baseline in phagocytic activity of
macrophages and PMN cells from peripheral blood and
serum levels of TNF-α and IL-12. The phagocytic activity
was determined using pHrodo™ E. coli BioParticles®
phagocytosis kit (Invitrogen) according to the manu-
facturer’s instructions. Levels of TNF-α and IL-12 in
serum were determined using each ELISA kit (R&D
Systems) according to the manufacturer’s instructions.
Safety parameters
Physical examination, vital signs, and laboratory mea-
surements for safety assessment were obtained at
every visit, and participants were also asked to report any
adverse events at any time. The laboratory measurements
included blood chemistry (BC), complete blood count
(CBC), and urinalysis. Electrocardiography was obtained at
baseline and week 14. Female volunteers of childbearing
age were subjected to urine human chorionic gonadotropin
test at screening. Any change from the baseline status was
defined as an adverse event, and the causality was assessed
as definite, probable, possible, probably not related,
definitely not related, and unknown. All adverse events
and serious adverse events were reported according to
current standards.
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Y-75 is isolated from the ethanol-insoluble fraction of
aqueous Panax ginseng extracts through an industrial
process under strict quality control. Y-75 obtained from
Dr. Yeon-Sook Yun of Health Biomed Inc. (Seoul, Korea),
is composed of approximately 75% glucose, 8% galactose,
6% arabinose, 0.4% glucuronic acid, and 11% galacturonic
acid. The test material was composed of freeze-dried pow-
der of Y-75 (1 g) and starch (1 g) as a diluting agent and
was packed to contain 2 g/package. The placebo used in
this study was composed of caramel syrup (0.03 g) and
starch (1.97 g) and was packed identically to the active
treatment. Volunteers were randomly assigned to receive
either Y-75 or placebo according to a randomization
list generated with SAS (SAS Institute Inc., USA). Medical
Excellence Inc. (Seoul, Korea), the contract research
organization maintained secure copies of the treatment
codes and also provided investigators with numbered
sealed envelopes containing the treatment codes. The
randomization codes were not decrypted until completion
of the study and data analysis.
Statistical analysis
Assuming an 8% increase (a standard deviation of 10%) in
NK cell cytotoxicity from baseline over an initial 8-week
treatment period of Y-75, a sample size of 29 participants
per group was calculated to provide 80% power to detectFigure 1 Flow-chart of the study.an difference between Y-75 and placebo groups (two-sided
α of 5%). Allowing for a dropout rate of 20%, enrollment
of 72 participants was considered sufficient.
The primary efficacy analysis was performed in the
intention-to-treat set and included all participants random-
ized with a baseline assessment. Data from study dropouts
was analyzed using the last observation carried forward
method. Efficacy analysis was performed with independent
t-test or Wilcoxon rank sum test. Differences from
baseline were analyzed with paired t-test or Wilcoxon’s
signed rank test.
Safety analyses were conducted to evaluate change from
baseline in the safety profile over 14 weeks. Safety data were
summarized using frequencies for categorical variables and
proportions as a percent. Pearson’s Chi-square test and
Fisher’s extract test were used to compare the proportions
of subjects reporting symptoms related to adverse events.
All analyses were conducted using SAS, version 9.3 (SAS
Institute Inc.) and were performed by a biostatistician.
Results
Participants
A total of 72 randomized, healthy volunteers partici-
pated in this study and were considered for safety and
intention-to-treat primary analyses. A total of 60 of the
initial study subjects completed all procedures, with a
dropout rate of 16.7 % comprising 12 withdrawals (7 with
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difference between the two sets of statistical results, for
which one was obtained from the intention-to-treat set and
the other from the per-protocol set. Baseline characteristics
of the participants are shown in Table 1. Characteristics
were similar between the Y-75 and placebo groups. The
study population had a mean age of 58.0 years and
was predominantly female (97.2%).
NK cell activity
NK cell activity was expressed as the percentage of lysed
target cells (Figure 2A). No significant differences were
observed in the baseline activities between Y-75 and
placebo group (38.5 ± 14.11% vs. 40.6 ± 13.4%; P = 0.5072).
After 8 and 14 weeks of Y-75 administration, NK cell
activities were significantly increased from baseline by
35.2% (P ≤0.0001) and 40.2% (P ≤0.0001), respectively.
Compared with placebo, the Y-75 group exhibited a
significantly higher NK cell activity at week 8 (52.0 ± 13.7%
vs. 40.8 ± 14.6%; P = 0.0012) and week 14 (53.9 ± 13.0% vs.
41.6 ± 15.5%; P = 0.0005).
Phagocytic activity
The amount of FITC-labeled E. coli phagocytized by
macrophages and PMNCs was expressed as arbitrary
numbers of fluorescence intensity (Figure 2B).Table 1 Summary of baseline clinical characteristics
Characteristics Y-75 (n = 36) Placebo
(n = 36)
Age, years 57.42 ± 4.09 58.69 ± 4.34
Female sex, n (%) 34 (94.44) 36 (100)
Weight, kg 58.39 ± 5.42 58.83 ± 7.18
Height, cm 157.56 ± 4.69 158.28 ± 4.99
Menopause, n (%) 27 (87.10) 32 (94.12)
Medical history, n (%)
Musculoskeletal and connective disease 12 33.33) 15 (41.67)
Cardiovascular disease 7 (19.44) 8 (22.22)
Metabolism and nutritional disease 5 (13.89) 6 (16.67)
Gastrointestinal disease 4 (11.11) 2 (5.56)
Vital sign
Systolic BP, mmHg 109.86 ± 10.72 108.89 ± 12.25
Diastolic BP, mmHg 75.69 ± 8.12 74.31 ± 9.79
Heart rate 69.78 ± 4.85 69.56 ± 6.22
WBC (109/L) 5.68 ± 1.47 5.25 ± 1.36
Neutrophils (%) 49.59 ± 11.17 49.48 ± 9.29
Lymphocytes (%) 39.63 ± 8.04 40.98 ± 8.69
Monocytes (%) 6.86 ± 1.56 6.58 ± 1.41
Eosinophils (%) 2.15 ± .55 2.46 ± 1.90
Basophils (%) 0.53 ± 0.38 0.50 ± 0.28
Data presented as mean ± SD of number (%). All differences were non-significant.Baseline phagocytic activity was 19632.1 ± 5227.1 and
20150.4 ± 6620.4 in the Y-75 and placebo groups,
respectively, and increased with Y-75 from baseline by 25.2%
(P = 0.0018) at week 8 and 39.4% (P ≤0.0001) at week 14.
Comparing between Y-75 and placebo group, the corre-
sponding values were 24585.3 ± 7597.2 versus 21615.4 ±
5662.6 (P = 0.0880) at week 8, and 27366.1 ± 7772.3 versus
21913.5 ± 6455.8 (P = 0.0018) at week 14.
Monocyte-derived mediators
At baseline, serum level of TNF-α was 2297.8 ±
1551.6 pg/ml for the Y-75 and 2322.9 ± 1861.9 pg/ml for
the placebo group. At week 8 and 14, Y-75 administration
increased the level of TNF-α from baseline by 38.2%
(P = 0.0006) and 44.5% (P = 0.0097), respectively.
Significant differences between the Y-75 and placebo
group were also observed at week 8 (3174.8 ± 1694.5
vs. 2286.4 ± 1769.3 pg/ml; P = 0.0329) and week 14
(3319.5 ± 1886.8 vs. 2360.3 ± 1552.6 pg/ml; P = 0.0319)
(Figure 2C).
In the serum IL-12 level assay, we obtained several
“undetectable” results that were subsequently excluded
from statistical analysis. This resulted in a difference in
the number of analyzed subjects between the scheduled
visits. As a result, paired-comparison of serum IL-12
level between before and after treatments was not
performed. The differences between the Y-75 and placebo
groups were not significant according to Wilcoxon rank
sum test, although higher levels of IL-12 were observed in
the Y-75 group (Figure 2D).
Adverse clinical events
Nineteen adverse events occurred in 9 participants given
Y-75 (14 events) and 5 participants given placebo (5 events),
consisting of 5 gastrointestinal problems (2 with placebo
and 3 with Y-75), 4 infections (1 with placebo and 3
with Y-75), 3 complaints of musculoskeletal system
pain (1 with placebo and 2 with Y-75); 2 headaches, 1
case of fatigue, and 1 foreign body aspiration in the
Y-75 group; and 1 case of insomnia, 1 eye disorder,
and 1 lipid metabolism disorder in the placebo group.
Among those, 1 event (dyspepsia) in placebo group
was classified as possibly related to the investigational
drug. There was no statistical difference between the two
groups for all adverse events (P = 0.2336), and no specific
severe adverse events were observed during the study
period (Table 2). Lastly, vital signs and laboratory findings
for safety, which included CBC, BC, and urinalysis, were
not statistically different between the two groups.
Discussion
Considerable current interest has focused on health
products that are believed to enhance immunity, and
ginseng is the most studied herbal medicine in this
Figure 2 Changes in cytotoxic activity of NK cells (A), activity of phagocytes (B), and monocyte-derived mediator (TNF-α and IL-12)
levels (C, D) during the study period. Data are mean ± SE. ** P <0.01 different from baseline, †P <0.05, †† P <0.01 different from the
placebo group.
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extract has limited clinical utility due to variations in
pharmacological effects depends on preparations [2,28].
Thus, efforts have been made to purify the active
components of ginseng in order to isolate its pharmaco-
logical constituents and achieve a more predictable outcome
after administration. Several immunomodulatory polysac-
charides have been isolated such as ginsenans [29-31],
CVT-E002 [32], and Ginsan [13]. Currently, CVT-E002 is
the only purified polysaccharide preparation for which safetyTable 2 Rates of adverse events during the study period




Volunteer with at least one adverse event, n (%) 9 (25.00) 5 (13.89)
Total number of adverse events 14 5
Clinical adverse event leading to discontinuation
of study drug
0 0
Serious adverse event 0 0
Probably drug-related adverse event 0 1
Most common adverse events
(with incidence >5% of volunteers), n (%)
Gastrointestinal disease 3 (8.33) 2 (6.25)
Infection 3 (8.33) 1 (2.78)
Musculoskeletal and connective disease 2 (6.25) 1 (2.78)and therapeutic effectiveness have been demonstrated in
clinical trials [33-36].
In the current study, we characterized the safety and
efficacy of Y-75, a novel candidate of immune modulator,
in 72 healthy volunteers. Administration of Y-75 for 8
and 14 weeks safely increased NK cell activity by 35.2%
and 40.2%, respectively, from baseline without altering
white blood cell differential count, electrolytes, or vital
signs or causing significant side effects. Importantly,
compared with placebo, NK cell activity was increased
by 27.6% and 29.6% at 8 and 14 weeks, respectively.
Secondary efficacy variables, phagocytosis of E. coli by
phagocytes from peripheral blood and serum level of
the representative monocyte-derived mediator TNF-α,
were also significantly increased by Y-75. These findings
are consistent with previous preclinical laboratory studies
on Ginsan.
In the current 14-week study, administration of Y-75
was well tolerated, with no discontinuation of therapy
due to adverse effects. The most commonly experienced
adverse events associated with usage of ginseng products
include headache, sleep disturbance, and gastrointestinal
disorders [37]. Long-term abuse of ginseng is associated
with hypertension, gastrointestinal disturbances, insomnia,
nervousness, confusion, and depression [38]. However, the
number of clinical events that occurred during this trial
Cho et al. Journal of Translational Medicine 2014, 12:283 Page 6 of 7
http://www.translational-medicine.com/content/12/1/283was small, and their distribution indicated that there were
no treatment-related adverse events. This high degree of
safety of Y-75 was expected based on clinical literature
showing that ginseng products are rarely associated with
adverse effects [39].
We did not address mechanisms of action in terms of a
target immune organ in the study design. Considering its
high molecular weight, Y-75 is unlikely to be absorbed
from the digestive tract into systemic circulation. How-
ever, in vitro evidence for gastrointestinal epithelial trans-
fer of oligosaccharides has been reported [40]. Therefore,
probable absorption of integrated molecule or digested
fragment with active moiety should not be excluded.
Furthermore, because the gastrointestinal tract is the largest
immune organ in the body, it is interesting to speculate
that this organ may be a direct target of Y-75 [41].
The pharmacokinetic profile of Y-75 after ingestion in
unknown, and thus there are several limitations in this
study. First, although preclinical laboratory observations
showed direct stimulation of immune effector cells by
Y-75, we cannot exclude the involvement of another
unknown substance or substances generated through
metabolism or transformation in the digestive system,
as in the case of ginsenosides [42]. Second, we were
also limited by uncertainty as to whether the designed
dosing schedule was optimized for a primary outcome.
Another limitation is gender imbalance between the
groups. Male subjects (n = 2) were included only in Y-75
group. We re-analyzed the primary efficacy excluding
the male subjects, and obtained the similar results;
51.3 ± 13.7% of NK cell activity with Y-75 versus 40.8 ± 14.6%
with placebo at week 8 (P = 0.0028), and 53.4 ± 13.1% versus
41.6 ± 15.5% at week 14 (P = 0.0010). However, a
study including a similar number of male in the both
groups is needed to exclude gender effect. Next limitation
is that the findings presented in this study, did not directly
reflect clinical utility as an anti-tumor or anti-septic alter-
native. Therefore, further investigation in larger trials
designed with respect to therapeutic outcome is needed.
Finally, the short study duration did not allow for predic-
tion of the long-lasting effects on the immune system or
the exclusion of emerging adverse events after long-term
administration.
Conclusions
Administration of Y-75 for 14 weeks induced augmenta-
tion in NK cell and phagocyte activities and cytokine re-
lease without affecting white blood cell differential counts
in healthy volunteers. In addition, we found no significant
adverse effects associated with Y-75. So far, these findings
are valid for normal individuals only. However, this
study provides the foundation for future clinical trials
aimed at assessing the therapeutic outcomes of Y-75
as an anti-tumor or anti-septic clinical utility.Abbreviations
IL-12: Interleukin-12; TNF-α: Tumor necrosis factor-α; NK: Natural killer;
PMN: Polymorphonuclear; FITC: Fluorescein isothiocyanate; BC: Blood
chemistry; CBC: Complete blood count.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
KSK designed the study and takes responsibility for the integrity of the data.
YJC participated in interpretation of results, and drafted the manuscript. HJS
performed in vitro assays for the assessment of immunity. All authors have
read and approved the final manuscript.
Acknowledgements
This work was supported by the Technological Innovation R&D Program
(SA114109) funded by the Small and Medium Business Administration
(SMBA, Korea). We thank a clinical research nurse Hwayoun Park for
coordination of this study. Statistical analysis was performed by
biostatisticians (MSc Youn-Ju Lee and MSc Hyewon Shin) employed by a
contract research organization, Medical Excellence Inc.
Author details
1Department of Family Medicine, Seoul St. Mary’s Hospital, The Catholic
University of Korea, Banpo-ro 222, Seocho-gu, Seoul 137-701, Republic of
Korea. 2Department of Biomedical Engineering, Korea University College of
Health Science, Anam-ro 145, Seongbuk-gu, Seoul 136-701, Republic of
Korea. 3Clinical Research Coordinating Center, CMC, The Catholic University
of Korea, Banpo-ro 222, Seocho-gu, Seoul 137-701, Republic of Korea.
Received: 17 June 2014 Accepted: 24 September 2014
References
1. Radad K, Gille G, Liu L, Rausch WD: Use of ginseng in medicine with
emphasis on neurodegenerative disorders. J Pharmacol Sci 2006,
100:175–186.
2. Jia L, Zhao Y: Current evaluation of the millennium phytomedicine–ginseng
(I): etymology, pharmacognosy, phytochemistry, market and regulations.
Curr Med Chem 2009, 16(19):2475–2484.
3. Kang S, Min H: Ginseng, the ‘Immunity Boost’: the effects of Panax
ginseng on immune system. J Ginseng Res 2012, 36(4):354–368.
4. Kim DH: Chemical Diversity of Panax ginseng, Panax quinquifolium, and
Panax notoginseng. J Ginseng Res 2012, 36(1):1–15.
5. Yin SY, Kim HJ, Kim HJ: A comparative study of the effects of whole red
ginseng extract and polysaccharide and saponin fractions on influenza A
(H1N1) virus infection. Biol Pharm Bull 2013, 36(6):1002–1007.
6. Yoo DG, Kim MC, Park MK, Park KM, Quan FS, Song JM, Wee JJ, Wang BZ,
Cho YK, Compans RW, Kang SM: Protective effect of ginseng
polysaccharides on influenza viral infection. PLoS One 2012, 7(3):e33678.
7. Wang Z, Meng J, Xia Y, Meng Y, Du L, Zhang Z, Wang E, Shan F: Maturation
of murine bone marrow dendritic cells induced by acidic Ginseng
polysaccharides. Int J Biol Macromol 2013, 53:93–100.
8. Byeon SE, Lee J, Kim JH, Yang WS, Kwak YS, Kim SY, Choung ES, Rhee MH,
Cho JY: Molecular mechanism of macrophage activation by red ginseng
acidic polysaccharide from Korean red ginseng. Mediators Inflamm 2012,
2012:732860.
9. Lim TS, Na K, Choi EM, Chung JY, Hwang JK: Immunomodulating activities
of polysaccharides isolated from Panax ginseng. J Med Food 2004,
7(1):1–6.
10. Shin HJ, Kim YS, Kwak YS, Song YB, Kim YS, Park JD: Enhancement of
antitumor effects of paclitaxel (taxol) in combination with red ginseng
acidic polysaccharide (RGAP). Planta Med 2004, 70(11):1033–1038.
11. Gao H, Wang F, Lien EJ, Trousdale MD: Immunostimulating
polysaccharides from Panax notoginseng. Pharm Res 1996,
13(8):1196–1200.
12. Du XF, Jiang CZ, Wu CF, Won EK, Choung SY: Synergistic
immunostimulating activity of pidotimod and red ginseng acidic
polysaccharide against cyclophosphamide-induced immunosuppression.
Arch Pharm Res 2008, 31(9):1153–1159.
Cho et al. Journal of Translational Medicine 2014, 12:283 Page 7 of 7
http://www.translational-medicine.com/content/12/1/28313. Yun YS, Lee YS, Jo SK, Jung IS: Inhibition of autochthonous tumor by
ethanol insoluble fraction from Panax ginseng as an immunomodulator.
Planta Med 1993, 59(6):521–524.
14. Lee YS, Chung IS, Lee IR, Kim KH, Hong WS, Yun YS: Activation of multiple
effector pathways of immune system by the antineoplastic
immunostimulator acidic polysaccharide ginsan isolated from Panax
ginseng. Anticancer Res 1997, 17(1a):323–331.
15. Ko EJ, Joo HG: Stimulatory effects of ginsan on the proliferation and
viability of mouse spleen cells. Korean J Physiol Pharmacol Off J Korean
Physiol Soc Korean Soc Pharmacol 2010, 14(3):133–137.
16. Kim MH, Byon YY, Ko EJ, Song JY, Yun YS, Shin T, Joo HG:
Immunomodulatory activity of ginsan, a polysaccharide of panax
ginseng, on dendritic cells. Korean J Physiol Pharmacol 2009, 13(3):169–173.
17. Kim HJ, Kim MH, Byon YY, Park JW, Jee Y, Joo HG: Radioprotective effects
of an acidic polysaccharide of Panax ginseng on bone marrow cells.
J Vet Sci 2007, 8(1):39–44.
18. Shin JY, Song JY, Yun YS, Yang HO, Rhee DK, Pyo S: Immunostimulating
effects of acidic polysaccharides extract of Panax ginseng on
macrophage function. Immunopharmacol Immunotoxicol 2002,
24(3):469–482.
19. Song JY, Han SK, Son EH, Pyo SN, Yun YS, Yi SY: Induction of secretory
and tumoricidal activities in peritoneal macrophages by ginsan.
Int Immunopharmacol 2002, 2(7):857–865.
20. Han SK, Song JY, Yun YS, Yi SY: Ginsan improved Th1 immune response
inhibited by gamma radiation. Arch Pharm Res 2005, 28(3):343–350.
21. Hwang I, Ahn G, Park E, Ha D, Song JY, Jee Y: An acidic polysaccharide of
Panax ginseng ameliorates experimental autoimmune encephalomyelitis
and induces regulatory T cells. Immunol Lett 2011, 138(2):169–178.
22. Kim KH, Lee YS, Jung IS, Park SY, Chung HY, Lee IR, Yun YS: Acidic
polysaccharide from Panax ginseng, ginsan, induces Th1 cell and
macrophage cytokines and generates LAK cells in synergy with rIL-2.
Planta Med 1998, 64(2):110–115.
23. Shim JY, Han Y, Ahn JY, Yun YS, Song JY: Chemoprotective and adjuvant
effects of immunomodulator ginsan in cyclophosphamide-treated
normal and tumor bearing mice. Int J Immunopathol Pharmacol 2007,
20(3):487–497.
24. Song JY, Han SK, Bae KG, Lim DS, Son SJ, Jung IS, Yi SY, Yun YS:
Radioprotective effects of ginsan, an immunomodulator. Radiat Res 2003,
159(6):768–774.
25. Na HS, Lim YJ, Yun YS, Kweon MN, Lee HC: Ginsan enhances humoral
antibody response to orally delivered antigen. Immune network 2010,
10(1):5–14.
26. Ahn JY, Song JY, Yun YS, Jeong G, Choi IS: Protection of Staphylococcus
aureus-infected septic mice by suppression of early acute inflammation
and enhanced antimicrobial activity by ginsan. FEMS Immunol Med
Microbiol 2006, 46(2):187–197.
27. Ahn JY, Choi IS, Shim JY, Yun EK, Yun YS, Jeong G, Song JY: The
immunomodulator ginsan induces resistance to experimental sepsis by
inhibiting Toll-like receptor-mediated inflammatory signals. Eur J
Immunol 2006, 36(1):37–45.
28. Qi LW, Wang CZ, Yuan CS: Isolation and analysis of ginseng: advances
and challenges. Nat Prod Rep 2011, 28(3):467–495.
29. Tomoda M, Hirabayashi K, Shimizu N, Gonda R, Ohara N: The core structure
of ginsenan PA, a phagocytosis-activating polysaccharide from the root
of Panax ginseng. Biol Pharm Bull 1994, 17(9):1287–1291.
30. Tomoda M, Hirabayashi K, Shimizu N, Gonda R, Ohara N, Takada K:
Characterization of two novel polysaccharides having immunological
activities from the root of Panax ginseng. Biol Pharm Bull 1993,
16(11):1087–1090.
31. Tomoda M, Takeda K, Shimizu N, Gonda R, Ohara N, Takada K, Hirabayashi K:
Characterization of two acidic polysaccharides having immunological
activities from the root of Panax ginseng. Biol Pharm Bull 1993,
16(1):22–25.
32. Yang JC, Pang CS, Tsang SF, Ng KF: Effect of American ginseng extract
(Panax quinquefolius) on formalin-induced nociception in mice. Am J
Chin Med 2001, 29(1):149–154.
33. High KP, Case D, Hurd D, Powell B, Lesser G, Falsey AR, Siegel R,
Metzner-Sadurski J, Krauss JC, Chinnasami B, Sanders G, Rousey S, Shaw EG:
A randomized, controlled trial of Panax quinquefolius extract (CVT-E002)
to reduce respiratory infection in patients with chronic lymphocytic
leukemia. J Support Oncol 2012, 10(5):195–201.34. McElhaney JE, Goel V, Toane B, Hooten J, Shan JJ: Efficacy of COLD-fX in
the prevention of respiratory symptoms in community-dwelling adults:
a randomized, double-blinded, placebo controlled trial. J Altern
Complement Med 2006, 12(2):153–157.
35. McElhaney JE, Gravenstein S, Cole SK, Davidson E, O’neill D, Petitjean S,
Rumble B, Shan JJ: A placebo-controlled trial of a proprietary extract of
North American ginseng (CVT-E002) to prevent acute respiratory illness
in institutionalized older adults. J Am Geriatr Soc 2004, 52(1):13–19.
36. McElhaney JE, Simor AE, McNeil S, Predy GN: Efficacy and Safety of
CVT-E002, a proprietary extract of Panax quinquefolius in the prevention
of respiratory infections in influenza-vaccinated community-dwelling
adults: a multicenter, randomized, double-blind, and placebo-controlled
trial. Influenza Res Treat 2011, 2011:759051.
37. Shergis JL, Zhang AL, Zhou W, Xue CC: Panax ginseng in randomised
controlled trials: a systematic review. Phytother Res 2013, 27(7):949–965.
38. Siegel RK: Ginseng abuse syndrome. Problems with the panacea.
JAMA 1979, 241(15):1614–1615.
39. Choi J, Kim TH, Choi TY, Lee MS: Ginseng for health care: a systematic
review of randomized controlled trials in Korean literature. PLoS One
2013, 8(4):e59978.
40. Eiwegger T, Stahl B, Haidl P, Schmitt J, Boehm G, Dehlink E, Urbanek R,
Szepfalusi Z: Prebiotic oligosaccharides: in vitro evidence for
gastrointestinal epithelial transfer and immunomodulatory properties.
Pediatr Allergy Immunol 2010, 21(8):1179–1188.
41. Jeurink PV, van Esch BC, Rijnierse A, Garssen J, Knippels LM: Mechanisms
underlying immune effects of dietary oligosaccharides. Am J Clin Nutr
2013, 98(2):572s–577s.
42. Wee JJ, Mee Park K, Chung AS: Biological Activities of Ginseng and Its
Application to Human Health. In Herbal Medicine: Biomolecular and Clinical
Aspects. Edited by Benzie IFF, Wachtel-Galor S. Boca Raton (FL): CRC Press
Llc; 2011.
doi:10.1186/s12967-014-0283-1
Cite this article as: Cho et al.: A 14-week randomized, placebo-
controlled, double-blind clinical trial to evaluate the efficacy and safety
of ginseng polysaccharide (Y-75). Journal of Translational Medicine
2014 12:283.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
